VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-WNV-PrM/E (dogs and cats)
Vaccine Information
  • Vaccine Name: ALVAC-WNV-PrM/E (dogs and cats)
  • Target Pathogen: West Nile virus
  • Target Disease: West Nile fever
  • Vaccine Ontology ID: VO_0004736
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • PrM gene engineering:
    • Type: Recombinant vector construction
    • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
    • Detailed Gene Information: Click Here.
  • E protein gene engineering:
    • Type: Recombinant vector construction
    • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
    • Detailed Gene Information: Click Here.
  • Vector: ALVAC vaccine vector
  • Preparation: Canarypox vector expressing PrM and E genes of West Nile virus (WNV) (ALVAC-WNV) (Karaca et al., 2005).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Dog Response

  • Vaccination Protocol: One group of 17 dogs was vaccinated with 105.6 TCID 50 (Karaca et al., 2005).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The animals were challenged 120 and 135 days after the second immunization, respectively via the bites of Aedes albopictus mosquitoes infected with WNV (Karaca et al., 2005).
  • Efficacy: The first dose of vaccine induced a detectable antibody response in four dogs and five cats (one immunized with low and four with high doses). After the second dose, all the vaccinated dogs and all of the cats, immunized with high dose had detectable antibody titers, whereas only four of eight cats in the low dose group were seropositive. None of the vaccinated dogs and one vaccinated cat developed viremia following the WNV mosquito-challenge. In contrast, 14 of the 15 control dogs and 9 of the 11 control cats developed viremia (Karaca et al., 2005).

Cat Response

  • Vaccination Protocol: Two groups of cats (groups 1 [n=14] vaccinated with 107.5 TCID(50) and 2 [n=8] 105.6 TCID(50)) were vaccinated twice at 28-day intervals (Karaca et al., 2005).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The animals were challenged 120 and 135 days after the second immunization, respectively via the bites of Aedes albopictus mosquitoes infected with WNV (Karaca et al., 2005).
  • Efficacy: The first dose of vaccine induced a detectable antibody response in four dogs and five cats (one immunized with low and four with high doses). After the second dose, all the vaccinated dogs and all of the cats, immunized with high dose had detectable antibody titers, whereas only four of eight cats in the low dose group were seropositive. None of the vaccinated dogs and one vaccinated cat developed viremia following the WNV mosquito-challenge. In contrast, 14 of the 15 control dogs and 9 of the 11 control cats developed viremia (Karaca et al., 2005).
References
Karaca et al., 2005: Karaca K, Bowen R, Austgen LE, Teehee M, Siger L, Grosenbaugh D, Loosemore L, Audonnet JC, Nordgren R, Minke JM. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine. 2005; 23(29); 3808-3813. [PubMed: 15893618].